Research programme: sordarin antifungals - Diversa
Alternative Names: DVSA 103; DVSA 105; DVSA 106; DVSA 107; DVSA 108; DVSA 109Latest Information Update: 14 May 2008
At a glance
- Originator GlaxoSmithKline
- Developer Diversa
- Class Indenes
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 31 Jan 2006 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 15 Nov 2004 Data presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2004) have been added to the Mycoses antimicrobial activity section ,
- 01 Mar 2004 Diversa's sordarins research programme is available for partnering in Asia (http://www.diversa.com)